Monday, January 9, 2017

CiVi Biopharma Takes $40M

San Francisco-based biopharmaceuticals developer CiVi Biopharma, a biopharmaceuticals firm which is targeting cardiometabolic diseases, has raised $40M in a funding round, the company said on Friday. The investment came from Boxer Capital of the Tavistock Group. The funds go towards completion of completion of pre-clinical and early phase I clinical development of its lead compound. More information »